Gabriele M. Cerrone
Gabriele M. Cerrone's purchase track record
Gabriele M. Cerrone has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/17/2022 | OKYO | $687K | -43.4% | -39.2% | -2.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
TLSA Doses First ALS Patients, Completes MS Trial Visits. Tiziana Life Sciences has started dosing patients in its intranasal foralumab ALS trial, with the first three participants receiving the first dose. The company also completed patient visits in its Phase 2a multiple sclerosis trials, including the INFORM‑MS study, and the last patient finished the final visit. Topline results from the MS trial are expected in October, which will give insight into the drug’s safety and effectiveness.
Transaction History
| OKYO | ▲ Buy | Grant | 22,500 | $33K | 7/21/2026 | View on chart |
| TLSA | ▲ Buy | Grant | 42,357 | $42K | 7/21/2026 | View on chart |
| OKYO | ▲ Buy | Grant | 25,000 | $35K | 7/20/2026 | View on chart |
| TLSA | ▲ Buy | Grant | 15,000 | $17K | 6/12/2026 | View on chart |
| OKYO | ▲ Buy | Grant | 300,000 | $516K | 6/8/2026 | View on chart |
| OKYO | ▼ Sell | Other | 70,071 | $105K | 10/27/2023 | View on chart |
| OKYO | ▼ Sell | Other | 499,468 | $749K | 10/23/2023 | View on chart |
| OKYO | ▲ Buy | Open Market | 5,800,000 | $441K | 5/19/2022 | View on chart |
| OKYO | ▲ Buy | Open Market | 37,500 | $150K | 5/19/2022 | View on chart |
| OKYO | ▲ Buy | Open Market | 1,625,000 | $97K | 5/17/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
OKYO Pharma to Present at Ophthalmic Scientific Conferences
OKYO Pharma announced it will present and participate in several upcoming ophthalmic scientific conferences. The company’s involvement highlights its focus on eye‑care products and may increase visibility among researchers and clinicians. This activity could support interest in OKYO’s pipeline as the firm seeks to advance its ophthalmic therapies.
OKYO Pharma to Present at Ophthalmic Scientific Conferences. OKYO Pharma announced it will present and participate in several upcoming ophthalmic scientific conferences. The company’s involvement highlights its focus on eye‑care products and may increase visibility among researchers and clinicians. This activity could support interest in OKYO’s pipeline as the firm seeks to advance its ophthalmic therapies.